SDB 005

SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB₁ and CB₂ cannabinoid receptors. SDB-005 is the indazole core analogue of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB-005 was originally used for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006. This compound is a potent agonist of the CB₁ receptor (Ki = 21 nM) and CB₂ receptor (Ki = 140 nM).

However SDB-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in Europe as a designer drug, and was entered into the EMCDDA synthetic drug database under this name. Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.